^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Immunostimulant

    Related drugs:
    1d
    A Phase 3 Study in India to Describe the Safety and Immunogenicity of RSVpreF (clinicaltrials.gov)
    P3, N=540, Not yet recruiting, Pfizer
    New P3 trial
    1d
    First-in-human, Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) Alone or in Combination With Pembrolizumab in Stage II-- III Triple Negative Breast Cancer Following Standard Therapy ( VITAL-TNBC ) (clinicaltrials.gov)
    P1, N=60, Recruiting, Immunomic Therapeutics, Inc.
    New P1 trial • First-in-human
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA (Breast cancer early onset)
    |
    HER-2 negative • ER negative • BRCA mutation
    |
    Keytruda (pembrolizumab)
    1d
    A clinical trial of V940 with or without MK-3475A in people with non-small cell lung cancer (V940-014) (2025-522643-18-00)
    P2/3, N=137, Recruiting, Merck Sharp & Dohme LLC
    New P2/3 trial
    |
    Keytruda (pembrolizumab) • intismeran autogene (mRNA-4157)
    1d
    Immunogenicity of Recombinant Vesicular Stomatitis Vaccine for Ebola-Zaire (rVSV∆G-ZEBOV-GP Vaccine) (clinicaltrials.gov)
    P2, N=248, Completed, National Institutes of Health Clinical Center (CC) | N=99 --> 248
    Enrollment change
    1d
    Supporting Weak Immune System During Autoimmune Therapy: Testing Panzyga to Prevent Infections (clinicaltrials.gov)
    P3, N=360, Not yet recruiting, Octapharma | Initiation date: Dec 2025 --> Jun 2026
    Trial initiation date
    1d
    Allogeneic, Antigen-Presenting, GM-CSF-secreting, SV-BR-1-GM Whole Cell-Therapeutic Vaccine and Immunotherapy (clinicaltrials.gov)
    P1, N=0, Withdrawn, Medical College of Wisconsin | N=20 --> 0 | Initiation date: Mar 2026 --> Jun 2026 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial initiation date • Trial withdrawal
    |
    Keytruda (pembrolizumab) • cyclophosphamide • Bria-IMT (SV-BR-1-GM) • ViraferonPeg (peginterferon-α-2b)
    2d
    Trial to Model Primary, Secondary, and Tertiary Dengue Using a Monovalent Vaccine (clinicaltrials.gov)
    P1, N=127, Completed, National Institutes of Health Clinical Center (CC) | Active, not recruiting --> Completed | Trial completion date: May 2026 --> Oct 2025
    Trial completion • Trial completion date
    2d
    Phase I Trial of Vididencel in CML-CP Patients With MRD Under TKI Treatment (clinicaltrials.gov)
    P1, N=24, Recruiting, Mendus
    New P1 trial
    |
    ABL1 (ABL proto-oncogene 1)
    |
    vididencel (DCP-001)
    3d
    Overall Survival of Patients With PSA-Recurrent Prostate Cancer: Long-Term Analysis of a Randomized Phase 2 Trial of pTVG-HP DNA Vaccine Versus Placebo. (PubMed, Clin Genitourin Cancer)
    These results suggest that pTVG-HP may have had a single-agent benefit that could not be appreciated using an MFS endpoint. This is consistent with results from other trials of anticancer vaccines, which suggest that these may have more impact on longer-term endpoints such as survival.
    P2 data • Journal
    |
    CSF2 (Colony stimulating factor 2) • PSAP (Prostatic Acid Phosphatase)
    |
    MVI-816
    3d
    Testing RG1-VLP Vaccine to Prevent HPV-related Cancers (clinicaltrials.gov)
    P1, N=18, Recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2027 --> Aug 2028 | Trial primary completion date: Jun 2026 --> Feb 2028
    Trial completion date • Trial primary completion date
    |
    Gardasil 9 (human papillomavirus 9-valent vaccine, recombinant)
    3d
    Contactin-1-Associated Membranous Nephropathy after Multiple mRNA 1273 COVID-19 Vaccinations: A Case Report. (PubMed, Glomerular Dis)
    To our knowledge, this is the first case report demonstrating a temporal association between contactin-1-associated membranous nephropathy and vaccination against COVID-19 with mRNA 1273. Our findings in this case broaden the clinical spectrum of the rare contactin-1-associated membranous nephropathy.
    Journal
    |
    CNTN1 (Contactin 1)
    3d
    A Clinical Trial of the 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid) (clinicaltrials.gov)
    P=N/A, N=100, Not yet recruiting, CanSino Biologics Inc.
    New trial